 |
Prospector
Profile
07.1179
|
| |
| Mymetics Corporation |
NAICS |
541710 |
| 14, rue de la Colombiere
Nyon, Switzerland 1260 |
Description |
Biotechnology |
| 011-41-22-363-1310 |
Employees |
3 |
| http://www.mymetics.com/ |
Revenue |
EUR(mil) |
0.0000 |
| |
Income |
EUR(mil) |
-1.5850 |
| |
Assets |
EUR(mil) |
0.3600 |
| |
Liability |
EUR(mil) |
6.8400 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Mymetics Corporation reported a net loss of EUR2,584,000 for the three months ended June 30, 2007, compared to a net loss of EUR373,000 during the same period last year. As a result of its recurring losses, the Company has an accumulated deficit of EUR18,656,000 and stockholder's deficit of EUR991,000. It also has strained liquidity with EUR306,000 in total current assets available to pay EUR1,612,000 in total current laibilities.
|
| |
|
Intellectual Property:
The Company owns intellectual property relating to its core business, which is focused on the development of novel HIV-AIDS preventive vaccines and therapeutics. Particularly, the Company has two issued French patents FR99 06528 and FR01 15424 on IL-2 mimicry; one European issued patent EP1034000 on IL-2 mimicry; and U.S. issued patent US 6,455,265 on gp41 & IL-2 mimicry. The Company also has filed two patents under the PCT for peptides rich in tryptophane as inhibitors of HIV infection from PFS and for describing gp41 peptides or proteins to block HIV fusion/infection. The Company has filed four United States provisional applications related to the field. On July 29, 2004, the Company applied for a new PCT which covers its mutated, trimeric, stable recombinant gp41 protein. On May 2, 2005, it also applied for a new PCT, which covers the description of IgA antibodies against recombinant gp41 protein. On March 3, 2006, the Company applied for a new PCT which covers its latest prototype HIV-AIDS preventive vaccine based on the usage of the virosome technology with HIV peptides and proteins. [SEC Filing 10-K 03-30-07]
|
| |
|
Description:
Mymetics is an international biotechnology company successfully focused on developing vaccines and therapies to combat AIDS.
|
| |
|
Officers:
Christian Rochet (Pres., CEO & Dir.); Ernst Luebke (CFO, Treas., Sec. & Dir.); Sylvain Fleury, Ph.D. (Chief Scientific Officer & Dir.)
|
| |
|
Auditor:
Peterson Sullivan LLC
|
| |
|
Securities:
Common Stock-Symbol MYMX.PK; Other OTC;
173,096,964 common shares outstanding as of July 17, 2007.
|
| |
| |
| |
| return to main page |
|
|
